Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature

The treatment landscape of chronic lymphocytic leukemia (CLL) has been challenged by the advent of novel classes of drugs, such as B-cell receptor (BCR)-inhibitors and BCL-2 antagonists. In selected high-risk patients, the choice to start allogeneic hematopoietic stem cell transplantation (alloHCT)...

Descripción completa

Detalles Bibliográficos
Autores principales: Annalisa, Arcari, Simona, Bassi, Lara, Pochintesta, Elena, Trabacchi, Filippo, Moroni Carlo, Angela, Rossi, Luca, Zanlari, Daniele, Vallisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5717301/
https://www.ncbi.nlm.nih.gov/pubmed/29234595
http://dx.doi.org/10.1016/j.lrr.2017.11.001
_version_ 1783284116930691072
author Annalisa, Arcari
Simona, Bassi
Lara, Pochintesta
Elena, Trabacchi
Filippo, Moroni Carlo
Angela, Rossi
Luca, Zanlari
Daniele, Vallisa
author_facet Annalisa, Arcari
Simona, Bassi
Lara, Pochintesta
Elena, Trabacchi
Filippo, Moroni Carlo
Angela, Rossi
Luca, Zanlari
Daniele, Vallisa
author_sort Annalisa, Arcari
collection PubMed
description The treatment landscape of chronic lymphocytic leukemia (CLL) has been challenged by the advent of novel classes of drugs, such as B-cell receptor (BCR)-inhibitors and BCL-2 antagonists. In selected high-risk patients, the choice to start allogeneic hematopoietic stem cell transplantation (alloHCT) or continue these agents is a matter of debate. Furthermore, published data about the impact on the feasibility of alloHCT and the optimal timing of administration are limited. Here we present a case of relapsed TP53 mutated CLL treated with ibrutinib as a bridge to alloHCT, discussing risks and benefits of different treatment options in a “real life” situation.
format Online
Article
Text
id pubmed-5717301
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-57173012017-12-11 Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature Annalisa, Arcari Simona, Bassi Lara, Pochintesta Elena, Trabacchi Filippo, Moroni Carlo Angela, Rossi Luca, Zanlari Daniele, Vallisa Leuk Res Rep Article The treatment landscape of chronic lymphocytic leukemia (CLL) has been challenged by the advent of novel classes of drugs, such as B-cell receptor (BCR)-inhibitors and BCL-2 antagonists. In selected high-risk patients, the choice to start allogeneic hematopoietic stem cell transplantation (alloHCT) or continue these agents is a matter of debate. Furthermore, published data about the impact on the feasibility of alloHCT and the optimal timing of administration are limited. Here we present a case of relapsed TP53 mutated CLL treated with ibrutinib as a bridge to alloHCT, discussing risks and benefits of different treatment options in a “real life” situation. Elsevier 2017-11-15 /pmc/articles/PMC5717301/ /pubmed/29234595 http://dx.doi.org/10.1016/j.lrr.2017.11.001 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Annalisa, Arcari
Simona, Bassi
Lara, Pochintesta
Elena, Trabacchi
Filippo, Moroni Carlo
Angela, Rossi
Luca, Zanlari
Daniele, Vallisa
Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature
title Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature
title_full Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature
title_fullStr Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature
title_full_unstemmed Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature
title_short Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature
title_sort ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: a case report and review of the literature
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5717301/
https://www.ncbi.nlm.nih.gov/pubmed/29234595
http://dx.doi.org/10.1016/j.lrr.2017.11.001
work_keys_str_mv AT annalisaarcari ibrutinibasabridgetotransplantinhighriskchroniclymphocyticleukemiaacasereportandreviewoftheliterature
AT simonabassi ibrutinibasabridgetotransplantinhighriskchroniclymphocyticleukemiaacasereportandreviewoftheliterature
AT larapochintesta ibrutinibasabridgetotransplantinhighriskchroniclymphocyticleukemiaacasereportandreviewoftheliterature
AT elenatrabacchi ibrutinibasabridgetotransplantinhighriskchroniclymphocyticleukemiaacasereportandreviewoftheliterature
AT filippomoronicarlo ibrutinibasabridgetotransplantinhighriskchroniclymphocyticleukemiaacasereportandreviewoftheliterature
AT angelarossi ibrutinibasabridgetotransplantinhighriskchroniclymphocyticleukemiaacasereportandreviewoftheliterature
AT lucazanlari ibrutinibasabridgetotransplantinhighriskchroniclymphocyticleukemiaacasereportandreviewoftheliterature
AT danielevallisa ibrutinibasabridgetotransplantinhighriskchroniclymphocyticleukemiaacasereportandreviewoftheliterature

Ejemplares similares